Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.56 |
| ▸ | ANO1 | Q5XXA6 | 4/20 | 0.54 |
| ▸ | GRM5 | P41594 | 6/20 | 0.53 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.52 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26922153 | 0.94 | ANO1 (0.58) | ANO1GRM5ACKR3NPC1RAB9A | |
| SCHEMBL26922393 | 0.92 | ANO1 (0.60) | ANO1GRM5ACKR3NPC1RAB9A | |
| SCHEMBL16038662 | 0.87 | GRM5 (0.49) | SMYD3ANO1GRM5KDM4CACKR3 | |
| SCHEMBL25592912 | 0.81 | SMYD3 (0.56) | SMYD3ANO1GRM5NPC1RAB9A | |
| SCHEMBL244667 | 0.80 | SMYD3 (0.66) | SMYD3ANO1GRM5ACKR3 | |
| SCHEMBL244445 | 0.78 | SMYD3 (0.67) | SMYD3ANO1GRM5 | |
| SCHEMBL15820978 | 0.78 | SMYD3 (0.53) | SMYD3ANO1GRM5NPC1RAB9A | |
| SCHEMBL19909568 | 0.78 | SMYD3 (0.53) | SMYD3ANO1GRM5NPC1RAB9A | |
| SCHEMBL2241357 | 0.78 | GRM5 (0.77) | SMYD3GRM5 | |
| SCHEMBL31224301 | 0.78 | SMYD3 (0.49) | SMYD3GRM5NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115594681-B | Isoindoline-1, 3-dione derivative and application thereof | 广州六顺生物科技有限公司 | 2024-06-18 | — | — | CN | disclosed |
| US-11858930-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-01-02 | — | — | US | disclosed |
| US-11858930-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-01-02 | — | — | US | disclosed |
| WO-2022023447-A2 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2022-02-03 | — | — | WO | disclosed |
| US-20220033398-A1 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE | 2022-02-03 | — | — | US | disclosed |
| US-9309224-B2 | N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20140275016-A1 | N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2014145029-A2 | N-ACYL-N'-(PYRIDIN-2-YL) UREAS AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033398-A1 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | BRAF, RAF1, NRAS | SMYD3 3211/4885ANO1 4728/4885GRM5 4437/4885 |
| US-11858930-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | BRAF, RAF1, NRAS | SMYD3 3211/4885ANO1 4728/4885GRM5 4437/4885 |
| US-20140275016-A1 | N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities | KIT, CSF1R, CSF3R | SMYD3 1629/4885ANO1 1403/4885GRM5 3876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.